StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet
Marketer
Sarvagunaushdhi Pvt Ltd
Salt Composition
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet
DiaBeta-Triple (Glimepiride 2mg/Metformin 500mg/Voglibose 0.3mg) tablets are an antidiabetic medication combination for adult type 2 diabetes management. This formulation helps regulate blood glucose levels. DiaBeta-Triple should be taken with food, consistently at the same time daily for optimal efficacy. Dosage is determined and adjusted by your physician based on your blood sugar response. Continued use is crucial; discontinuation without medical supervision may elevate blood sugar, risking kidney problems, vision loss, nerve damage, and limb complications. This medication complements a comprehensive diabetes management plan incorporating diet, exercise, and weight management as directed by your doctor. Lifestyle modifications are pivotal in diabetes control. Hypoglycemia (low blood sugar) is a common side effect, characterized by sweating, dizziness, headache, and tremors. Regular meals and readily available glucose sources (e.g., sugary foods or juice) are essential. Alcohol consumption increases hypoglycemia risk and should be limited. Other potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, bone fractures, upper respiratory infections, and weight gain. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, and severe kidney or liver disease. Individuals with a history of heart disease should consult their physician before use. Pregnant or breastfeeding individuals require medical consultation prior to use. Regular blood sugar monitoring and blood tests (to assess blood cell counts and liver function) are typically recommended.
Primary Ingredients of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet
No information provided. Please provide the text you wish to be rewritten.
Uses of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet
Managing type 2 diabetes
Major Benefits of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet on an empty stomach.
Common Side effects of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet:
Administer this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg tablets on an empty stomach.
How StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet works:
Tri-action diabetic medication StayHappi combines glimepiride (2mg), metformin (500mg), and voglibose (0.3mg) in a single tablet.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while taking StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The use of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg tablets during pregnancy may pose risks. While human research is limited, animal studies indicate potential harm to a developing fetus. A physician will assess the potential advantages against the risks before prescribing this medication. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The use of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg tablets while breastfeeding is likely inadvisable. Available evidence from human studies indicates potential transfer of the medication into breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
The combined medication StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet poses a likely risk for individuals with kidney impairment and its use should be prevented. Seek medical advice before use. This medication is contraindicated in patients exhibiting severe kidney dysfunction.
LiverCAUTION
Patients with liver impairment should use StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg tablets cautiously, potentially requiring dosage modification. Consult a physician. For those with mild to moderate liver disease, initiation should be at a low dose; the medication is unsuitable for patients with severe liver disease.
What if you forget to take StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet :
Should you forget a StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet dose, administer it promptly. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.3mg Tablet
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | Diabetes Management |
3,018 People bought this recently